Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer by Ceelen, Wim et al.
Preoperative chemoradiation versus radiation alone for stage
II and III resectable rectal cancer (Review)
Ceelen WP, Van Nieuwenhove Y, Fierens K
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2009, Issue 1
http://www.thecochranelibrary.com
Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 1 Overall Survival at 5y. . . . . . . 15
Analysis 1.2. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 2 Disease free survival at 5 y. . . . . . 16
Analysis 1.3. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 3 Mortality 30 d. . . . . . . . . . 16
Analysis 1.4. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 4 Postop morbidity. . . . . . . . . 17
Analysis 1.5. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 5 Grade III - IV toxicity. . . . . . . 17
Analysis 1.6. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 6 Sphincter preservation. . . . . . . 18
Analysis 1.7. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 7 pCR. . . . . . . . . . . . . 18
Analysis 1.8. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 8 Anastomotic leak. . . . . . . . . 19
Analysis 1.9. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 9 Local Recurrence at 5y. . . . . . . 19
19WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iPreoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Preoperative chemoradiation versus radiation alone for stage
II and III resectable rectal cancer
Wim P Ceelen1, Yves Van Nieuwenhove2, Kjell Fierens3
1Dept. of Surgery 2K12 1C, Ghent University Hospital, Ghent, Belgium. 2Department of Experimental Surgery, Free University of
Brussels, Brussels, Belgium. 3Dept. of Surgery 2K12 1c, Ghent University Hospital, Ghent, Belgium
Contact address: Wim P Ceelen, Dept. of Surgery 2K12 1C, Ghent University Hospital, De Pintelaan 185, Ghent, B-9000, Belgium.
wim.ceelen@ugent.be.
Editorial group: Cochrane Colorectal Cancer Group.
Publication status and date: New, published in Issue 1, 2009.
Review content assessed as up-to-date: 1 September 2008.
Citation: CeelenWP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable
rectal cancer. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006041. DOI: 10.1002/14651858.CD006041.pub2.
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Preoperative radiotherapy (RT) decreases local recurrence rate and improves survival in stage II and III rectal cancer patients. The
combination of chemotherapy with RT has a sound radiobiological rationale, and phase II trials of combined chemoradiation (CRT)
have shown promising activity in rectal cancer.
Objectives
To compare preoperative RT with preoperative CRT in patients with resectable stage II and III rectal cancer.
Search strategy
We searched the Cochrane Central Register of Controlled Trials, Web of Science, Embase.com, and Pubmed from 1975 until june
2007. A manual search was performed of Ann Surg, Arch Surg, Cancer, J Clin Oncol, Int J Radiat Oncol Biol Phys and the proceedings
of ASTRO, ECCO and ASCO from 1990 until june 2007.
Selection criteria
Relevant studies randomized resectable stage II or III rectal cancer patients to at least one arm of preoperative RT alone or at least one
arm of preoperative CRT.
Data collection and analysis
Primary outcome parameters included overall survival (OS) at 5 years and local recurrence (LR) rate at 5 years. Secondary outcome
parameters included disease free survival (DFS) at 5 years, metastasis rate, pathological complete response rate, clinical response rate,
sphincter preservation rate, acute toxicity, postoperative mortality and morbidity, and anastomotic leak rate. Outcome parameters were
summarized using the Odds Ratio (OR) and associated 95% confidence interval (CI) using the fixed effects model.
Main results
Four trials were identified and included in the meta-analysis. The addition of chemotherapy to preoperative RT significantly increased
grade III and IV acute toxicity (OR 1.68-10, P = 0.002) while no differences were observed in postoperative morbidity or mortality.
Compared to preoperative RT alone, preoperative CRT significantly increased the rate of complete pathological response (OR 2.52-
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5.27, P < 0.001) although this did not translate into a higher sphincter preservation rate (OR 0.92-1.31, P = 0.29). The indidence of
local recurrence at five years was significantly lower in the CRT group compared to RT alone (OR 0.39-0.72, P < 0.001). No statistically
significant differences were observed in DFS (OR 0.92-1.34, P = 0.27) or OS (OR 0.79-1.14, P = 0.58) at five years.
Authors’ conclusions
Compared to preoperative RT alone, preoperative CRT enhances pathological response and improves local control in resectable stage
II and III rectal cancer, but does not benefit disease free or overall survival. The effects of preoperative CRT on functional outcome
and quality of life are incompletely understood and should be addressed in future trials.
P L A I N L A N G U A G E S U M M A R Y
Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
In rectal cancer patients, local control is improved by administering radiotherapy (RT) before surgery. Recently, studies have combined
preoperative RT with chemotherapy aiming to further improve local control. This review compared preoperative RT with preoperative
chemoradiation (CRT) in patients with stage II and III rectal cancer.
Based on the combined analysis of four randomized studies, we found that compared to preoperative RT alone, preoperative CRT
enhances pathological response and improves local control in resectable stage II and III rectal cancer, but does not benefit disease free
or overall survival. Combined CRT enhances treatment related acute toxicity, but does not affect postoperative complication rate. The
effects of preoperative CRT on functional outcome and quality of life are incompletely understood and should be addressed in future
trials.
B A C K G R O U N D
The incidence of fatal cases of colorectal cancer in Europe exceeds
200.000 per year. Due to the specifc anatomy and biology of rec-
tal cancer, surgery alone historically has been associated with local
recurrence in up to one in four patients. Locally recurrent dis-
ease is usually incurable, causes important morbidity and suffer-
ing and gives rise to systemic metastases. In the last few decades,
improvements in surgical technique have dramatically lowered the
incidence of locally recurrent disease. Careful pathological studies
have clearly demonstrated that the major cause of local recurrence
is the persistence of tumor foci within the mesorectum (Quirke
1986; Quirke 2003). Intact removal of the entire mesorectum (to-
tal mesorectal excision or TME) in cancers of the mid or lower
third of the rectum was pioneered by Heald and has resulted in lo-
cal recurrence rates lower than 5-10% (Heald 1982; Heald 1998;
Enker 1999). The importance of complete removal of the sur-
rounding mesorectum necessitates precise preoperative evaluation
of the circumferential resection margin using imaging. Recently,
magnetic resonance imaging (MRI) using a phased array coil has
emerged as the imagign modality of choice in the preoperative
evaluation of locally advanced rectal cancer Beets-Tan 2003; Beets-
Tan 2005; Brown 2004; Daniels 2005; Brown 2006).
Parallel to improvements in surgical technique, adjuvant therapy
regimens have been tested in clinical trials in an effort to reduce
local recurrence rates. Neoadjuvant radiotherapy (RT) has been
shown to significantly decrease local recurrence rate and improve
survival provided a biologically equivalent dose (BED) of at least
30 Gy is administered (Gray 2001). The advantages of preopera-
tive over postoperative RT include enhanced effectiveness in well
oxygenated tissue, downstaging of advanced tumors and better
treatment compliance (Glimelius 2002). This theoretical superior-
ity of the preoperative approach over postoperative adjuvant ther-
apy has been confirmed in the recent German rectal cancer trial
(Sauer 2004). The effect of preoperative RT on local recurrence
rate is consistent even when optimal surgical technique (TME) is
implemented. This was demonstrated by the results of the Dutch
rectal cancer trial which randomized rectal cancer patients to un-
dergo either RT followed by TME or TME alone in the setting of
a national surgical training programme (Kapiteijn 2001). Com-
pared to TME alone, 5x5 Gray (Gy) of RT followed by TME
resulted in a significantly lower local recurrence rate, although no
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improvement in overall survival (OS) was noted.
Although preoperative RT results in a significant pathological re-
sponse in a minority of patients, significant downsizing is rarely
achieved using short schedule RT regimens. In order to improve
tumor response, preoperative RT has been combined with chemo-
therapeutic regimens. There is a strong radiobiological rationale
to combine RT with chemotherapy. Combined chemoradiation
(CRT) for rectal cancer was introduced in the adjuvant setting and
subsequently in irresectable disease, where significant downsizing
and downstaging was observed in many patients (Minsky 1993;
Minsky 1997). The argument for preoperative CRT in resectable
disease is based primarely on possible downsizing and downstag-
ing of tumors close to the circumferential resection margin or the
sphincter apparatus, thereby enhancing both R0 resection and the
sphincter preservation rate. The paramount importance of per-
forming the resection with a negative CRM was shown in several
clinical studies (Nagtegaal 2002). Secondly, the addition of che-
motherapy could eliminatemicroscopic systemic disease present at
the time of surgery. Possible concerns of preoperative CRT include
an increase of both local and systemic toxicity and overtreatment
of inaccurately staged patients (Ammann 2003). Several phase I
and II studies using preoperative CRT have shown a promising
tumor response with acceptable toxicity (Rodel 2003; Osti 2004).
A limited number of prospective randomized trials comparing pre-
operative RT alone with preoperative CRT in resectable rectal can-
cer are published or ongoing.
O B J E C T I V E S
To compare preoperative RT with preoperative CRT in patients
with resectable stage II or III rectal cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCT’s) which randomize patients
before surgery with curative intent to one of at least two schedules
of preoperative therapy including RT and CRT.
Types of participants
Patients with clinical stage II or III resectable rectal cancer under-
going preoperative RT or CRT followed by surgery.
Types of interventions
Preoperative RT or CRT using fractionated external radiotherapy
followed by surgery with curative intent (resectable rectal can-
cer). The surgical procedure must consist of rectal amputation or
sphincter preserving anterior resection using an open or laparo-
scopic approach; local excisions are excluded.
Types of outcome measures
Primary
-local recurrence rate at 5 years
Secondary
-overall survival at 5 years
-disease free survival at 5 years
-systemic metastasis rate
-pathological complete response rate
-clinical response rate
-sphincter preservation rate
- postoperative mortality within 30 days
- postoperative morbidity
- anastomotic leak rate
Search methods for identification of studies
See: Colorectal Cancer Group methods used in reviews.
We searched the following electronic databases
-Cochrane Central Register of Controlled Trials
-ISI Web of Science (Science Citation Index, Current Contents)
from 1975 until june 2007
-Embase.com
-Pubmed
Electronic database searches were performed with MeSH terms
and free text terms:
-MeSH: \Rectal Neoplasms“[MeSH] AND\
Radiotherapy”[MeSH] AND \Drug Therapy“[MeSH]
-Free text terms:
rectal, rectum, cancer, adenocarcinoma, neoplasm, radiotherapy,
irradiation, chemotherapy, chemoradiation, radiochemotherapy,
combined modality, multimodal,preoperative,neoadjuvant
Manual search/abstract search
- Journals from 1990: Ann Surg, Arch Surg, Cancer, J Clin Oncol,
Int J Radiat Oncol Biol Phys
- Proceedings from ASTRO, ECCO and ASCO
No language constraints were applied.
Data collection and analysis
All three reviewers (WPC, KF, YVN) obtained the full text of
all relevant studies and were assessed for methodological quality
according to the Cochrane Collaboration’s tool for assessing the
risk of bias (Higgins 2008). Methodological details relevant for
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potential bias included sequence generation, allocation conceal-
ment, bliniding, incomplete outcome data, and selective outcome
reporting. Disagreement was resolved by consensus.
Data were extracted by one reviewer (KF) on custom designed
forms and entered in a computer database for transfer and statis-
tical analysis in the Review Manager software. The data extracted
included first author, year of publication, source, method of pre-
operative therapy and surgery, method of randomization, number
of patients included, randomized, and analyzed, and outcome pa-
rameters as listed above. Data accuracy was verified by the senior
author (WPC).
RT dose was converted to the biologically equivalent dose (BED)
using the linear quadratic equivalent formula (Dale 2005): BED
= nd(1+1/(α/β)-(γ /α)(T-Tk ), with n = number of fractions, d
= dose per fraction, α/β = the linear quadratic quotient (set at
10 Gy), γ /α= repair rate (set at 0.6 Gy/d), and Tk = the initial
time delay in days (set at 7). Differences between categorical out-
come parameters were quantified using the odds ratio (OR) and
corresponding 95% confidence interval (95CI). Summary statis-
tics were calculated using the Mantel-Haenszel methods. Hetero-
geneity analysis was performed using the Q test, with significance
accepted when P<0.1. When present, heterogeneity will be ad-
dressed as recommended by the Cochrane Collaboration Hand-
book (Higgins 2008).
R E S U L T S
Description of studies
See: Characteristics of included studies.
Of a total of 17925 studies resulting from the primary search,
324 papers were selected for full review. In all, 320 papers were
discarded (Table 1). Four randomized trials were identified com-
paring preoperative RT with preoperative CRT is resectable stage
II or III rectal cancer (Bosset 2006; Boulis-Wassif 1984; Bujko
2006; Gerard 2006).
Table 1. excluded studies
Type N
Non randomized trials 144
Adjuvant therapy trials 28
Trials not including at least one chemotherapy arm combinedwith
radiotherapy
71
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Table 1. excluded studies (Continued)
Trials not including radiotherapy 27
Trials using local or no resection 18
Trials including other tumor types 25
Trials not including stage II/III cancer 7
Total 320
From November 1972 through April 1976, Boulis-Wassif et
al. recruited 247 patients with histologically proven localized ade-
nocarcinoma of the rectum and no clinical of surgical evidence of
distant metastases. All patients in both groups received preoper-
ative RT by two parallel opposing diamond and chimney fields.
All patients received a total dose of 34.5 Gy in 15 fractions of 2.3
Gy each over a total treatment time of 18 days (BED = 35.8 Gy).
In the preoperative CRT group, intravenous 5-FU injection (375
mg/m2) was administered during the first 4 days of irradiation.
Surgery usually followed within 2 weeks after the last irradiation.
Two patients died before surgery. Assessed outcomes included ease
of surgery, type of operation, radical resectability rate, histopatho-
logical response, postoperative mortality, postoperative period of
hospitalization, local control of the disease, distant metastases, dis-
ease free survival, and median survival. Follow-up was available up
to 7 years.
From April 1999 until February 2002, Bujko et al. included 316
patients with resectable T3-T4 rectal carcinoma without sphinc-
ter infiltration and with a lesion accessible to digital rectal exami-
nation. Patients were randomised to either preoperative 5 x 5 Gy
short-term RT (BED = 37.5 Gy) with subsequent total mesorectal
excision (TME) performed within 7 days or to CRT to a total
dose of 50.4 Gy (1.8 Gy per fraction during 25 days; BED = 42.2
Gy) concomitantly with two courses of bolus 5-fluorouracil (325
mg/m2) and leucovorin during weeks 1 and 5 of RT. Chemora-
diation was followed by TME after 4-6 weeks. Three patients did
not undergo surgery. Assessed outcomes were acute postirradia-
tion toxicity, sphincter preservation rate, postoperative mortality,
pathology, overall survival, disease free survival, local recurrence
rate, distant metastases, late toxicity and incidence of permanent
stoma. Median follow up was 48 months.
Between April 1993 and November 2003, Gerard et al. recruited
762 patients with a histologically confirmed, previously untreated
rectal adenocarcinoma accessible to digital rectal examination (T3
or resectable T4 tumor with no evidence of distant metastases).
Patients were allocated to two treatment arms: preoperative RT
vs. preoperative CRT, both followed by surgery. RT was delivered
with photons from a linear accelerator in a three- or four-field box
technique. The dose per fraction was 1.8 Gy and all fields were
treated each day with five fractions per week. The total dose was
45 Gy in 25 fractions during 5 weeks (BED = 42.2 Gy). Concur-
rent chemotherapy (CT) consisted of bolus 5-fluorouracil (350
mg/m2) and leucovorin administered during week 1 and 5 of RT.
Surgery was planned between 3 and 10 weeks after the end of the
preoperative RT (+/- CT). TME was recommended. Assessed out-
comes were surgical procedures and postoperative complications,
pathology, overall survival, progression frees survival and local re-
currence. Median follow-up was 81 months.
Between April 1993 and March 2003, Bosset et al. recruited 1011
patients with a T3 or resectable T4 M0 adenocarcinoma of the
rectum within 15 cm from the anal margin and without previous
treatment for this disease (EORTC 22921 trial). Patients were
allocated to four treatment arms: preoperative RT, preoperative
CRT, preoperative RT plus postoperative CT and preoperative
CRT plus postoperative CT. RT consisted of 45 Gy delivered to
the posterior pelvis in 25 fractions of 1.8 Gy over a period of
5 weeks (BED = 42.2 Gy). The target volume of RT was not a
classical pelvic volume but was limited to the main field of tumor
spread and to the perirectal nodes. Preoperative chemotherapy was
delivered in two 5-day courses of 5-fluorouracil (350mg/m2) with
leucovorin during the first and fifth weeks of RT. Surgery was
scheduled to take place 3 to 10 weeks after treatment. TME was
recommendedbeginning in 1999. Assessed outcomeswere toxicity
of the preoperative treatment, performed surgical procedures, rate
of postoperative complications, pathology, late side effects, overall
survival, disease free survival, local and distant recurrence rate.
Median follow-up of 5.4 years.
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Risk of bias in included studies
Randomisation was adequately performed in all four studies us-
ing communication with a central office. Three studies based ran-
domisation on the minimization method (Bujko 2006; Gerard
2006; Bosset 2006). In the fourth study, the randomisation
method is not specified (Boulis-Wassif 1984). None of the studies
were described as doube blind or used blinded outcome assess-
ment.. Description of withdrawals and dropouts was given in all
four studies. There were no imbalances between treatment arms
in the number of patients that did not undergo the complete trial
procedure. Three studies were performed on an intention-to-treat
basis (Bujko 2006; Gerard 2006; Bosset 2006); no imbalances
were identified between treatment arms.
Effects of interventions
The main primary outcome parameter was the local recurrence
rate at five years, which was reported in three studies (Bosset 2006;
Boulis-Wassif 1984; Gerard 2006). In the RT group, 122 of 740
patients (16.5%) developed a local recurrence while in the CRT
group this event was observed in 71 out of 754 patients (9.4%).
This differencewas statistically significant (OR0.53, 95%CI 0.39-
0.72, P < 0.001). No statistically significant heterogeneity among
studies was present (P = 0.12). Survival data at 5 years were avail-
able in three studies (Bosset 2006; Boulis-Wassif 1984; Gerard
2006). In the CRT group, 644 of 1007 patients (63.9%) were
alive at 5 years while in the RT group 647 of 993 patients (65.2%)
survived 5 years. This difference did not reach statistical signifi-
cance (OR 0.95, 95%CI 0.79-1.14, P = 0.58). No heterogeneity
was present (P = 0.15).
The results of the analysis of the secondary outcome parameters
were as follows. Disease free survival at 5 years, available in the
studies of Bosset 2006 and Gerard 2006, was 507/881 (57.5%)
in the CRT group and 479/872 (54.9%) in the RT group. This
difference was not statistically significant (OR 1.11, 95%CI 0.92-
1.34, P = 0.27). Significant heterogeneity did not occur (P =
0.64). Grade III or IV treatment related toxicity developed in
151 of 1015 patients (14.9%) treated with CRT while in patients
treatedwith RT alone, this occurred in 52 of 1017 patients (5.1%).
This difference was statistically significant (OR 4.1, 95%CI 1.68-
10, P = 0.002). There was, however, significant heterogeneity (P
= 0.005) which remained when the data were reanalysed using
the random effects assumption. Among patients who underwent
surgery, sphincter preservation was possible in 551 of 1111 pa-
tients (49.6%) in the CRT group and in 527 of 1108 patients
(47.6%) in the RT group; this difference failed to reach statistical
significance (OR 1.1, 95%CI 0.92-1.31, P = 0.29). No hetero-
geneity was observed (P = 0.48). Postoperative 30 day mortality
was observed in 31 of 1122 (2.8%) patients in th CRT group and
in 21 of 1117 (1.9%) patients in the RT group. This difference
did not reach statistical significance (OR 1.48, 95%CI 0.84-2.6,
P = 0.17); no heterogeneity was detected (P = 0.6). Similarly, no
significant differences were observed in postoperative morbidity
or anastomotic leak rate (OR 0.68-1.03, P = 0.1 and OR 0.57-
1.85, P = 0.93 respectively). Pathological complete response (ie,
ypT0N0) of the resected specimen was observed in 129 of 1096
patients (11.8%) in the CRT group and in 39 of 1105 patients
(3.5%) in the RT group. This difference was statistically signif-
icant (OR 3.65, 95%CI 2.52-5.27, P < 0.001) while significant
heterogeneity for this parameter was not observed (P = 0.15).
Because of the limited number of included studies, no sensitivity
analysis was performed.
D I S C U S S I O N
Preoperative RT has been shown to reduce local recurrence rates
and marginally improve survival over surgery alone provided a
BED > 30 Gy is delivered to the target region (Gray 2001). The
current review addresses the question whether the addition of che-
motherapy to preoperative RT further enhances pathological and
clinical outcome parameters. Four randomized trials were iden-
tified comparing preoperative CRT with preoperative RT alone
in resectable, locally advanced rectal cancer. Although there was
considerable variation in radiotherapy dose and fractionation, all
four studies have used a BED > 30 Gy. In three trials (Gerard
2006; Boulis-Wassif 1984; Bosset 2006), RT regimens were iden-
tical in both groups. In the Polish study (Bujko 2006), RT dose
and fractionation and time interval until surgery were different in
both groups (5x5 Gy followed by immediate surgery versus 50.4
Gy followed by surgery after a waiting period of 4-6 weeks). In
this study, therefore, it remains unclear whether the observed dif-
ferences in tumor response between both arms are attributable to
the addition of chemotherapy or to a different RT schedule and
a different waiting period until surgery. Since, moreover, actuarial
local recurrence data at five years are not available in this study, it
was left out from the meta-analysis of local recurrence at five years.
This analysis demonstrates a significant reduction in local recur-
rence rate with the addition of chemotherapy (OR 0.39-0.72, P <
0.001). Importantly, the cumulative incidence rates of local recur-
rence in the RT group of the studies of Bosset 2006 and Gerard
2006 (17%) and in both groups of the study of Boulis-Wassif 1984
(15%) seem high compared to the 5.5% local recurrence rate at
five years achieved by the Dutch rectal cancer trial using 5x5 Gy
preoperative RT followed by surgery (van den Brink 2004). Dif-
ferences in stage distribution and variation in surgical technique
might explain this observation. Indeed, during the Dutch rectal
cancer trial a formal surgical training and quality control program
was implemented in order to guarantee optimal surgery (TME).
The study of Boulis-Wassif 1984 predated the introduction of
TME surgery (inclusion period 1972-1976), whereas in the stud-
ies of Bosset 2006 and Gerard 2006, TME surgery was ’recom-
mended’ without any formal surgical training or quality control.
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Although in the study of Boulis-Wassif 1984 a marginally signifi-
cant five year survival benefit was associated with CRT, the com-
bined analysis failed to demonstrate a significant difference in ei-
ther overall or disease free survival at five years (OR 0.79-1.14, P
= 0.58 and OR 0.92-1.34, P = 0.27, respectively). One of the hy-
potheses formulated to explain the observed lack of survival bene-
fit found in many pre- or postoperative adjuvant therapy trials in
rectal cancer is the existence of early, subclinical systemic disease
present at diagnosis. This hypothesis is supported by the finding
that the rate of distant metastatic disease in all four trials is consis-
tently around 30%, without any difference between CRT and RT
groups, indicating a future role of more effective systemic ther-
apy to eradicate micrometastatic disease from the onset of therapy.
Others have argued that the follow up time of the included trials
is too short to observe a survival benefit, or that the incidence of
local recurrence is too low to influence survival (Gerard 2006).
Grade III and IV acute treatment related toxicity was more pro-
nounced in the CRT group in the three studies reporting this pa-
rameter (Bosset 2006; Bujko 2006; Gerard 2006), with an overall
OR of 1.68-10 and a P value of 0.002. However, chemotherapy
related toxicity was generally acceptable as evidenced by the high
compliance rates in the studiesmentioned (82%, 78.1%, and 69%
respectively). In resected patients, no differences were observed
in 30 day mortality, postoperative morbidity, or anastomotic leak
rate. The results concerning anastomotic leakage should be in-
terpreted with caution, since the exceedingly low leakage rate in
the study of Bosset compared to currently accepted and published
leakage rates following anterior resection suggests underreporting
of this specific complication.
Postoperative quality of life (QoL) is an important, though of-
ten underreported aspect of cancer trials. From the Swedish and
Dutch rectal cancer trials, it is known that preoperative 5x5 Gy
followed by surgery significantly worsens functional outcome in
terms of bowel, sexual, and bladder function compared to surgery
alone (Holm 1996; Dahlberg 1998; Peeters 2005). A number of
phase II trials have suggested that preoperative CRT followed by
surgery does not adversely affect functional outcome (Feliu 2002;
Bosset 2000). The scarce available data in the four included stud-
ies did not allow to perform a meta-analysis fo QoL related pa-
rameters. However, preliminary functional outcome data of the
EORTC 22921 study (published as abstract only) demonstrated a
significantly worse anorectal function in CRT patients compared
to RT alone (Mercier 2005). Interestingly, in the final results pa-
per of this study the incidence of ’late side effects’ including fecal
incontinence did not seem to differ between the four treatment
arms (Bosset 2006).
The results of the meta-analysis confirm the enhanced cytotoxic
efficacy of combined RT with 5-fluorouracil based chemother-
apy. The incidence of a complete pathological response (pCR,
ypT0N0) was 129 of 1096 (11.8%) patients in the CRT group
and 39 of 1105 (3.5%) patients in the RT group; this difference
was statistically highly significant (OR 3.65, 95%CI 2.52-5.27, P
< 0.001) while no heterogeneity was observed between the four
studies. The results of the EORTC study moreover confirmed
the difference in radioresponsiveness of the tumor in the bowel
wall compared to that of mesorectal lymph nodes, as evidenced
by nodal involvement in up to 12% of ypT0 patients (Bosset
2004). Although in two studies (Bosset 2006; Boulis-Wassif 1984)
a trend towards increased sphincter preservation was observed in
the CRT group, the overall results failed to demonstrate an in-
crease in sphincter preserving surgery following CRT (OR 0.92-
1.31, P = 0.29), notwithstanding the downsizing and downstaging
effect often noted with the combined therapy. This finding may
be related to reluctance of the colorectal surgeon to alter a preoper-
ative assessment of the need to perform a rectal amputation, since
reversal of this decision would possibly imply performing an anas-
tomosis in previously macroscopically invaded tissue. Moreover,
in at least two studies was it specifically advised not to change a
preoperative decision to perform a rectal amputation even after a
significant downsizing. Data from the German rectal cancer trial,
however, suggested that a change in operative strategy (ie, perform
sphincter preserving surgery when a significant clinical response
is observed) may be safely performed. Longer follow up will be
needed to confirm the safety of this approach.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Compared to preoperative RT alone, preoperative CRT enhances
tumor reponse and improves local recurrence rates. Therefore, the
addition of CT should be considered when the tumor is located
close (< 2 mm) to the circumferential resection marging or the
sphincter apparatus. The addition of chemotherapy causes a mod-
erate increase in acute toxicity, although postoperative complica-
tions including anastomotic leakage are not enhanced.
At this moment, it is unclear from the available data whether the
addition of chemotherapy to preoperative RT influences sphinc-
ter preservation. Patients should be informed about the possible
functional and QoL related aspects of preoperative therapy.
Implications for research
1. Since the improvement of local control obtained with CRT did
not translate into a better overall or disease free survival and up to
one third of all patients develop distant spread, priority should be
given to trials addressing early subclinical systemic spread;
2. Trials are needed that specifically address the oncological safety
of performing sphincter preserving surgery (including intersphinc-
teric resection and colo-anal anastomosis) in patients deemed to
require amputation before the start of CRT and in whom a sig-
nificant clinical response is observed;
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3. Preoperative therapy trials in rectal cancer should include formal
evaluation of functional and QoL related aspects of therapy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bosset 2006
Methods 1.Randomization method: telephone to central office (assumed)
2. Abdominal imaging: CT
3. Chest imaging: CXR
4. 4 arm study: Arm 1 preop RT + S; Arm 2 preop XRT + concurrent 5FU LV + S;Arm 3 preop RT + S
+ post op 5FU LV ; Arm 4 preop RTCT+ S + postop 5FU LV
5. Total randomized 1011
Participants 1. Rectal Cancer
2. Location: within 15 cm from anal verge
3. Resectability: locally resectable
4. T3 or resectable T4 (defined by clinical criteria or endoscopic ultrasound)
5. WHO PS 0-1
6. </=80yr
Interventions 1.Surgery: AP/anterior resection or Hartman with TME
2. RT : 45 Gy in 25fr.
3. RT volume: 5cm above and below tumor and perirectal nodes below S2-3. If tumor above 10cm,
include
only 3 cm above tumor. If tumor in low rectum, S2-3 to perineum. Posteriorly to include entire sacrum
with 3cm beyond macroscopic extension
4. RT-S: within 3-10 weeks of completing neoadjuvant therapy
5. 3 or 4 field
6. Chemotherapy: 5FU 325mg/m2/d; Leucovorin 20mg/m2/day Dy1-5 & 28-32 for arms 2 and 4, and
postoperative for arms 3 and 4
Outcomes 1. Duration of FU: 5.4 yrs
2. Perioperative mortality: CRTS 2.4 % (12/506) RTS 1.2% (6/505)
3. Mets (liver) @ lap: Y
4. Curative resection: not stated
5. Overall resection: 94.5 %
6. Compliance to radiotherapy: CRTS 483/506 (95.5%) RTS 495/505 (98.0%)
7. OAS: Y
8. CSS?
9. Tox post RT: Y
10. Acute tox post S: Y
11. Late tox post S: Y
12. LR: Y
13. QOL: N
14. Proportion sfincter sparing: CRTS 267/506 (52.8%) RTS 255/505 (50.5%)
15. Proportion downstaging: Y
Notes
Risk of bias
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Bosset 2006 (Continued)
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Boulis-Wassif 1984
Methods 1.Randomization method: not stated. conducted by cooperative group. Likely via central office
2. Abdominal imaging: Not stated
3. Chest imaging: Not stated
4. Study arm (Preop chemoradiotherapy arm) : 171randomized, 45 excluded.
5. Control arm (Preop radiotherapy arm): 168 randomized , 47 excluded
Participants 1. Rectal Cancer
2. Location: below within 15cm anal verge
3. Resectability: fit for surgery
Interventions 1.Surgery: AP/anterior resection
2. RT : 3450 cGy in 15fr. (for both arms)
3. BED: 35.2Gy1
4. RT volume: ”chimney and diamond fields“ paraaortics and pelvis.
5. RT-S: within 2 wk
6. 2 field
7. Cointervention: none
8. 2 arms, control (Radiotherapy followed by surgery), Study (Chemoradiotherapy followed by surgery)
9.Chemotherapy: 5FU 10mg/kg/d day 1-4
Outcomes 1.Duration of FU: mean 5.2yrs
2. Perioperative mortality: CRTS 19/126 RTS 11/121
3. Mets @ lap: CRTS 13/126 RTS 15/121
4. Curative resection: Not stated
5. Overall resection: CRTS 121, RTS 124
6. Compliance to radiotherapy: not given
7. OAS: Y
8. CSS: N
9. Tox post RT: not given
10: Acute tox post S: not given
No complication not given
11. Late tox post S: not given
12: LR: N
13. QoL:N
Notes
Risk of bias
Item Authors’ judgement Description
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Boulis-Wassif 1984 (Continued)
Allocation concealment? Yes A - Adequate
Bujko 2006
Methods 1.Randomization method: telephone to central office
2. Abdominal imaging: ultrasound or CT
3. Chest imaging: CXR
4. XRT + S arm : (short XRT)155 randomized, 0 excluded.
5. Arm B: (Long XRT+CT): 157 randomized , 0 excluded
Participants 1. Rectal Cancer
2. Location: inferior edge palpable of digital exam
3. Resectability: locally resectable
4. T3 or resectable T4
5. not involving sphincter
Interventions 1.Surgery: AP/anterior resection or Hartman with TME
2. RT : XRT +S arm: 2500cGy cGy in 5fr. ; Arm B: 50.4Gy in 28 fr with concomitant CT weeks 1 & 5
3. BED: Arm A 38.7Gy10, Arm B 40.9Gy10
4. RT volume: Not stated
5. RT-S: XRT+S within 7 days; Arm B: within 4-6 weeks
6. 3 or 4 field
7. Arm B chemotherapy: 5FU 325mg/m2/d; Leucovorin 20mg/m2/day Dy1-5 & 28-32
Outcomes 1.Duration of FU: not stated
2. Perioperative mortality: XRT+S 0/155 Arm B 0/157
3. Mets @ lap: not stated
4. Curative resection: not stated
5. Overall resection: XRT+S 145/155 Arm B 147/157
6. Compliance to radiotherapy: XRT+S 152/155 Arm B 141/157
7. OAS: N
8. CSS: N
9. Tox post RT: no complications XRT+S 118/155 Arm B 24/157 Any complications XRT+S 37/155
Arm
B 133/157 Gd 3-4 XRT + S 5/155 Arm B 26/157 Gd 5 (Death) XRT +S 0/155 Arm B 2/157
10: Acute tox post S: Not stated
11. Late tox post S: not given
12: LR: N
13. QoL:N
14. Proportion sphincter sparing
15. Proportion downstaged (by T stage, N stage, Tumor size)
Notes
Risk of bias
Item Authors’ judgement Description
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Bujko 2006 (Continued)
Allocation concealment? Yes A - Adequate
Gerard 2006
Methods 1.Randomization method: not stated
2. Abdominal imaging: liver sonography - CT scan
3. Chest imaging: CXR
4. Study arm: CRT 375
5. Control arm: RT 367
Participants 1. Rectal Cancer
2. Location: accessible by digital examination
3. Resectability: locally resectable
Interventions 2 arms: preop XRT vs preop CRT
1.Surgery: TME recommended
2. RT 45Gy in 25 fr for both arms
3. BED: 32.5Gy10
4. RT volume: NA
5. RT-S: NA
6. NA
7. Cointervention: postoperative CT (5FU FA) x 4 cycles
Outcomes 1.Duration of FU: 81m
2. Perioperative mortality (60 days): 2% for both arms
3. Mets @ lap: not stated
4. Curative resection: not stated
5. Overall resection: not stated
6. Compliance to radiotherapy: not stated
7. OAS: Y
8. CSS: Y
9. Tox (gr 3-4) post RT: Preop RT arm: 10/367 CRT arm: 55/375
10: Acute tox post S: not stated
11. Late tox post S: Y
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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D A T A A N D A N A L Y S E S
Comparison 1. radiotherapy vs radiochemotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall Survival at 5y 3 2000 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.79, 1.14]
2 Disease free survival at 5 y 2 1753 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.92, 1.34]
3 Mortality 30 d 4 2239 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.84, 2.60]
4 Postop morbidity 3 1994 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.68, 1.03]
5 Grade III - IV toxicity 3 2032 Odds Ratio (M-H, Random, 95% CI) 4.10 [1.68, 10.00]
6 Sphincter preservation 4 2219 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.92, 1.31]
7 pCR 4 2201 Odds Ratio (M-H, Fixed, 95% CI) 3.65 [2.52, 5.27]
8 Anastomotic leak 3 1068 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.57, 1.85]
9 Local Recurrence at 5y 3 1494 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.39, 0.72]
Analysis 1.1. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 1 Overall Survival at 5y.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 1 Overall Survival at 5y
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosset 2006 333/506 327/505 48.1 % 1.05 [ 0.81, 1.36 ]
Boulis-Wassif 1984 58/126 71/121 16.8 % 0.60 [ 0.36, 0.99 ]
Gerard 2006 253/375 249/367 35.2 % 0.98 [ 0.72, 1.34 ]
Total (95% CI) 1007 993 100.0 % 0.95 [ 0.79, 1.14 ]
Total events: 644 (Treatment), 647 (Control)
Heterogeneity: Chi2 = 3.78, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.55 (P = 0.58)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.2. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 2 Disease free survival at 5 y.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 2 Disease free survival at 5 y
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosset 2006 284/506 275/505 59.1 % 1.07 [ 0.83, 1.37 ]
Gerard 2006 223/375 204/367 40.9 % 1.17 [ 0.88, 1.57 ]
Total (95% CI) 881 872 100.0 % 1.11 [ 0.92, 1.34 ]
Total events: 507 (Treatment), 479 (Control)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.3. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 3 Mortality 30 d.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 3 Mortality 30 d
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosset 2006 12/487 6/483 29.0 % 2.01 [ 0.75, 5.40 ]
Boulis-Wassif 1984 11/124 6/121 27.3 % 1.87 [ 0.67, 5.22 ]
Bujko 2006 1/152 2/153 9.8 % 0.50 [ 0.04, 5.57 ]
Gerard 2006 7/359 7/360 33.9 % 1.00 [ 0.35, 2.89 ]
Total (95% CI) 1122 1117 100.0 % 1.48 [ 0.84, 2.60 ]
Total events: 31 (Treatment), 21 (Control)
Heterogeneity: Chi2 = 1.86, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.4. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 4 Postop morbidity.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 4 Postop morbidity
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosset 2006 111/487 112/483 44.7 % 0.98 [ 0.73, 1.32 ]
Bujko 2006 31/152 39/153 15.9 % 0.75 [ 0.44, 1.28 ]
Gerard 2006 75/359 97/360 39.4 % 0.72 [ 0.51, 1.01 ]
Total (95% CI) 998 996 100.0 % 0.84 [ 0.68, 1.03 ]
Total events: 217 (Treatment), 248 (Control)
Heterogeneity: Chi2 = 1.99, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.096)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.5. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 5 Grade III - IV toxicity.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 5 Grade III - IV toxicity
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Bosset 2006 67/483 37/495 38.4 % 1.99 [ 1.31, 3.04 ]
Bujko 2006 29/157 5/155 28.0 % 6.80 [ 2.56, 18.07 ]
Gerard 2006 55/375 10/367 33.6 % 6.14 [ 3.08, 12.24 ]
Total (95% CI) 1015 1017 100.0 % 4.10 [ 1.68, 10.00 ]
Total events: 151 (Treatment), 52 (Control)
Heterogeneity: Tau2 = 0.49; Chi2 = 10.57, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 3.10 (P = 0.0019)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.6. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 6 Sphincter preservation.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 6 Sphincter preservation
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosset 2006 263/473 249/475 45.5 % 1.14 [ 0.88, 1.47 ]
Boulis-Wassif 1984 13/124 6/121 2.2 % 2.24 [ 0.82, 6.11 ]
Bujko 2006 87/157 87/155 16.1 % 0.97 [ 0.62, 1.52 ]
Gerard 2006 188/357 185/357 36.1 % 1.03 [ 0.77, 1.39 ]
Total (95% CI) 1111 1108 100.0 % 1.10 [ 0.92, 1.31 ]
Total events: 551 (Treatment), 527 (Control)
Heterogeneity: Chi2 = 2.48, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.7. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 7 pCR.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 7 pCR
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosset 2006 60/473 22/476 55.7 % 3.00 [ 1.81, 4.97 ]
Boulis-Wassif 1984 6/126 3/121 8.5 % 1.97 [ 0.48, 8.05 ]
Bujko 2006 22/138 1/148 2.4 % 27.88 [ 3.70, 209.90 ]
Gerard 2006 41/359 13/360 33.5 % 3.44 [ 1.81, 6.54 ]
Total (95% CI) 1096 1105 100.0 % 3.65 [ 2.52, 5.27 ]
Total events: 129 (Treatment), 39 (Control)
Heterogeneity: Chi2 = 5.24, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 6.89 (P < 0.00001)
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Analysis 1.8. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 8 Anastomotic leak.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 8 Anastomotic leak
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosset 2006 2/267 0/255 2.3 % 4.81 [ 0.23, 100.71 ]
Bujko 2006 8/87 9/86 37.7 % 0.87 [ 0.32, 2.36 ]
Gerard 2006 14/188 14/185 59.9 % 0.98 [ 0.45, 2.12 ]
Total (95% CI) 542 526 100.0 % 1.03 [ 0.57, 1.85 ]
Total events: 24 (Treatment), 23 (Control)
Heterogeneity: Chi2 = 1.11, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
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Analysis 1.9. Comparison 1 radiotherapy vs radiochemotherapy, Outcome 9 Local Recurrence at 5y.
Review: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Comparison: 1 radiotherapy vs radiochemotherapy
Outcome: 9 Local Recurrence at 5y
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosset 2006 22/253 43/252 35.2 % 0.46 [ 0.27, 0.80 ]
Boulis-Wassif 1984 19/126 18/121 14.0 % 1.02 [ 0.51, 2.04 ]
Gerard 2006 30/375 61/367 50.8 % 0.44 [ 0.27, 0.69 ]
Total (95% CI) 754 740 100.0 % 0.53 [ 0.39, 0.72 ]
Total events: 71 (Treatment), 122 (Control)
Heterogeneity: Chi2 = 4.24, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 4.03 (P = 0.000057)
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